ClinicalTrials.gg
CompletedNCT05141994Updated Apr 16, 2024

Clinical Study on the Efficacy and Safety of BAT5906 Injection

A Phase 2 interventional study of 2.5mg of BAT5906 and 4mg of BAT5906 in Wet Age-related Macular Degeneration, sponsored by Bio-Thera Solutions. Completed at 16 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Bio-Thera Solutions · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Enrollment
53rd of 91
48 · median 62
Started
2020
with 4 others
Phase 2
14 of 106
4 open now
Registered
40th of 106
by date
Lead sponsor
3 of 106
Bio-Thera Solutions

Among the 106 studies in Macular Degeneration with a site in China, this one is the 53rd largest by enrollment of the 91 interventional ones that give a count, is one of 5 that started in 2020, is one of 14 in phase 2, and was the 40th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, open, and phase II clinical study to evaluate the efficacy and safety of BAT5906 injection in patients with wet age-related macular degeneration. The results of the BAT5906 Phase I study show that it is safe from 0.3-4.0 mg, and that higher doses (2.5 mg and 4 mg) may be substituted for the duration of maintenance efficacy; drugs with the same target (such as brolucizumab and Abecip) have also been found in clinical studies High doses can extend the interval and reduce the frequency of administration. Therefore, in this study, two doses with better safety and efficacy were selected, once every 4 weeks, followed by 3 consecutive injections for treatment as needed, and preliminary exploration of the best clinical effective dose and replacement frequency

03

Conditions studied

  • Wet Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Only the following criteria are met:

    1. The patient or his legal representative authorized by the patient signs the , fully understands the test content, process and possible adverse reactions, and is willing to follow up within the time specified in the test;
    2. Age 50-85 years old (including boundary value), male or female;
    3. The patient diagnosed with active choroidal neovascularization (CNV) disease secondary to wet age-related macular degeneration is confirmed by the reading center during screening;
    4. The total area of research eye lesions ≤ 30mm2 (12 optic disc areas), confirmed by the reading center before random enrollment;
    5. At the time of screening and baseline, the BCVA of the study eye was 73-24 letters (using the ETDRS visual acuity table, including the boundary value) (equivalent to the snellen visual acuity score of the study eye of 20/40 to 20/400);
    6. At the time of screening and baseline, the contralateral eye BCVA ≥ 34 letters (using the ETDRS visual acuity table, which is equivalent to snellen vision ≥ 20/200). For the subjects in the PK group, the investigator must judge that the contralateral eye is expected to be 3 No anti-VEGF treatment is required within a month.

Exclusion criteria

Exclusion Criteria:

  • If a patient meets any of the following conditions, they cannot enter the study:

Those with the following eye conditions:

  1. The research eye has map-like atrophy involving the fovea, scars or fibrosis, anterior macular membrane, dense exudate hard exudation, RPE tear, etc. (confirmed by the reading center during screening);
  2. Research eye retinal hemorrhage ≥ 4 optic disc areas (confirmed by the reading center during screening);
  3. The research eye has significant interference with vision detection, anterior segment and fundus assessment of the refractive medium is turbid or the pupil is not dilated;
  4. The research eye is combined with other fundus diseases (such as diabetic retinal degeneration, retinal vein occlusion, vascular streaking, pathological myopia, retinal detachment, macular hole, toxoplasmosis, optic nerve disease, etc.);
  5. The research eye has pupil afferent defects (APD)
  6. There are uncontrolled glaucoma in the research eye at the time of screening and baseline, defined as the intraocular pressure is still higher than 21mmHg after drug treatment, or according to the investigator's judgment;
  7. The pre-screening research eye had received dexamethasone intravitreal implant (Ozurdex) treatment or fluocinolone intravitreal implant (Iluvien) treatment;
  8. Within 3 months before the screening, the research eye had received the following treatments: photodynamic therapy (PDT), total retina laser photocoagulation, macular laser photocoagulation, transpupillary thermotherapy, etc., for AMD therapy;
  9. The research eye has undergone the following ophthalmic operations: vitrectomy, macular transposition, anti-glaucoma surgery;
  10. Have undergone external eye surgery or cataract surgery within 3 months before the study eye screening or during the study period;
  11. The study eye has no lens (excluding intraocular lens) or posterior lens capsule rupture (except YAG laser posterior capsulotomy after implantation of intraocular lens more than 1 month after screening);
  12. Contralateral eye received photodynamic (PDT) treatment within 1 month before screening;
  13. A history of uveitis in any eye;
  14. Vitreous hemorrhage in any eye during the screening period or history of vitreous hemorrhage within 4 weeks before baseline;
  15. Any eye has pseudocapsular exfoliation syndrome;
  16. Any eye has active eye infection (eg: blepharitis, infectious conjunctivitis, keratitis, scleritis, iridocyclitis, endophthalmitis);
  17. Within 3 months before the screening, any eye had received intravitreal injection of anti-VEGF drugs (such as abecept, compaq, ranibizumab, bevacizumab, etc.);
  18. Injection of drugs (such as triamcinolone acetonide, dexamethasone, etc.) into any eye, periocular or subconjunctival eye within 3 months before screening;

    Those with any of the following general conditions:

  19. Currently in use or may need to use systemic drugs that may cause crystal toxicity or retinal toxicity, such as deferoxamine, chloroquine/hydroxychloroquine, phenothiazine, ethambutol or tamoxifen, etc.;
  20. Have an allergic reaction or history of fluorescein sodium and indocyanine green, have a history of allergy to protein products for treatment or diagnosis, or are known to have allergic reactions to any monoclonal antibody;
  21. Previously received systemic anti-VEGF treatment;
  22. Patients with large doses of oral or injectable corticosteroids and other hormonal drugs (>10 mg prednisolone or the same dose/day) within 6 months before screening, but patients who use steroid drugs for inhalation, nasal cavity or local skin small doses except;
  23. Poorly controlled diabetic patients are defined as > 10%;
  24. Those who had surgery within 1 month before screening and did not heal, or according to the judgment of the investigator;
  25. There are systemic infectious diseases that require intravenous antibiotic therapy;
  26. Those who have a history of myocardial infarction, cerebral infarction and angina within 6 months before screening;
  27. Those who have active disseminated intravascular coagulation and obvious bleeding tendency within 3 months before screening, or have received anticoagulant and antiplatelet therapy except aspirin/NSAIDs within 14 days before screening;
  28. Hypertension patients with poor control (defined as blood pressure >160/100 mmHg after treatment with antihypertensive drugs);
  29. Any uncontrollable clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other system diseases and malignant tumors);

    Those with abnormalities in any of the following laboratory tests:

  30. Abnormal liver and kidney function (this test stipulates that and AST shall not be higher than the value of the laboratory in the center by 2.5 times; Crea and BUN shall not be higher than the upper limit of the normal value of the laboratory in the center by 2 times);
  31. Patients with abnormal blood coagulation function (> upper limit of normal value 3 seconds or activated partial thromboplastin time> upper limit of normal value 10 seconds);
  32. Any one of the following infected patients: active (if HBsAg(+) requires HBV DNA must be >500 IU/mL or the hospital maximum limit), , AIDS or syphilis (syphilis RPR positive test) ;

    Women and men of childbearing age in any of the following situations:

  33. Women who are pregnant, pregnant or breastfeeding (pregnancy is defined as a positive blood/urine pregnancy test in this trial); male or female subjects of fertility do not agree to the entire study period and within 3 months after the end of the visit period Take appropriate measures (such as IUDs, birth control pills or condoms, etc.). For women who have not been menopausal or have been menopausal but have not met the menopause time continuously for more than 12 months, and have not undergone sterilization surgery (ovarian and/or hysterectomy), they are defined as having fertility. The definition of fertility may be adjusted according to local standards in each region.

    Note: High-efficiency contraception methods include total abstinence, IUD, double barrier method (eg condom + diaphragm with spermicides, implanted contraceptives, hormonal contraceptives [contraceptives, implanted contraceptives, transdermal Patches, hormone-vaginal appliances or sustained-release injections], or the partner has undergone vasectomy and is confirmed to have no sperm); other:

  34. Those who have participated in clinical trials of any drugs (excluding vitamins and minerals) within 3 months before screening;
  35. The researchers believe that those who need to be excluded.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    2.5mg of BAT5906

    Specification: 10mg/0.2ml/piece; route: intravitreal injection; dose: 2.5mg/eye/time, 50μl; medication duration: about once every 4 weeks, taking 3 times after continuous use, effective observation to Week 48.

    Drug: 2.5mg of BAT5906

  • Experimental
    4.0mg of BAT5906

    16mg/0.2ml/piece; route of administration: intravitreal injection; dose: 4.0mg/eye/time, 50μl; duration of administration: once every 4 weeks, 3 times after continuous administration , The effectiveness was observed to the 48th week.

    Drug: 4mg of BAT5906

Interventions

  • Drug2.5mg of BAT5906

    Specification: 2.5mg of BAT5906

  • Drug4mg of BAT5906

    Specification: 4mg of BAT5906

06

What researchers measure

Primary outcomes

  1. Dose-response relationships

    Trend chart of changes in the best corrected visual acuity from baseline

    Time frame: week 24

Secondary outcomes

  1. BCVA

    the best corrected visual acuity

    Time frame: week 12 ,week 48

  2. CRT

    The mean thickness of the central retina with a diameter of 1mm, centered on the fixed point of view

    Time frame: week 12 ,week 24,week 48

  3. 95% confidence interval

    The estimated interval of the population parameters constructed from the sample statistics

    Time frame: week 12 ,week 24,week 48

  4. Average times of administration

    The times of administration of each dose group were summarized

    Time frame: week 24,week 48

Other outcomes

  1. Pharmacokinetic(Cmax)

    Pharmacokinetic parameters

    Time frame: up tp week 48

  2. Pharmacokinetic(Tmax)

    Pharmacokinetic parameters

    Time frame: up tp week 48

  3. Pharmacokinetic(AUC0-Tau)

    Pharmacokinetic parameters

    Time frame: up tp week 48

  4. Pharmacokinetic(AR)

    Pharmacokinetic parameters

    Time frame: up tp week 48

  5. Pharmacokinetic(DF)

    Pharmacokinetic parameters

    Time frame: up tp week 48

  6. Pharmacokinetic(t1/2)

    Pharmacokinetic parameters

    Time frame: up tp week 48

  7. Pharmacokinetic(Vz)

    Pharmacokinetic parameters

    Time frame: up tp week 48

  8. Pharmacokinetic(Vss)

    Pharmacokinetic parameters

    Time frame: up tp week 48

  9. Pharmacokinetic(CL)

    Pharmacokinetic parameters

    Time frame: up tp week 48

  10. VEGF

    Peripheral vascular endothelial growth factor analysis

    Time frame: up tp week 48

  11. ADA

    Immunogenicity analysis

    Time frame: up tp week 48

07

Study locations

16 sites
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100730, China
  • Eye Hospital of China Academy of Chinese Medical Sciences
    Beijing, China
  • Peking University First Hospital
    Beijing, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, China
  • Jieyang People's Hospital
    Jieyang, China
  • The First Hospital of Jilin University
    Jilin, China
  • he Affiliated Eye Hospital of Nanchang University
    Nanchang, China
  • Jiangsu Provincial Hospital of Traditional Chinese Medicine
    Nanjing, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, China
  • Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong
    Shantou, China
  • West China Hospital of Sichuan University
    Sichuan, China
  • Wenzhou Medical University Affiliated Optometry Hospital
    Wenzhou, China
  • The Second Xiangya Hospital of Central South University
    Xiangya, China
  • Henan Provincial Eye Hospital
    Zhengzhou, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Sep 2022, 24 months.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 24 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2020
First posted
Dec 2, 2021
StartActual
Aug 26, 2020
Primary completionActual
Sep 6, 2022
CompletionActual
Sep 6, 2022
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05141994
Responsible party
Sponsor
First posted
Dec 2, 2021
Start date
Aug 26, 2020
Primary completion
Sep 6, 2022
Completion
Sep 6, 2022
Last update
Apr 16, 2024

Study contacts

Youxin Chen
principal investigator · Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion